Insulinoma differential diagnosis: Difference between revisions
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]] like [[altered mental status]]/[[confusion]], profuse [[sweating]] and visual disturbances ([[Blurred vision|blurring]]/[[diplopia]]). | Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]] like [[altered mental status]]/[[confusion]], profuse [[sweating]] and visual disturbances ([[Blurred vision|blurring]]/[[diplopia]]). These are classified on the basis of [[laboratory]] findings into exogenous [[insulin]], [[oral hypoglycemic agent]]<nowiki/>s (e.g. [[sulphonylurea]]<nowiki/>s), [[nesidioblastosis]], insulin autoimmune hypoglycemia. | ||
==Differentiating insulinoma from other Diseases== | ==Differentiating insulinoma from other Diseases== | ||
*Insulinoma must be differentiated from other diseases that cause features of hypoglycemia. These are classified on the basis of laboratory findings. | *Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]]. These are classified on the basis of [[laboratory]] findings. | ||
===Differentials for [[Hypoglycemia]] on the basis of Laboratory findings<ref name="pmid19088155">{{cite journal| author=Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER et al.| title=Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 3 | pages= 709-28 | pmid=19088155 | doi=10.1210/jc.2008-1410 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19088155 }} </ref>:=== | ===Differentials for [[Hypoglycemia]] on the basis of Laboratory findings<ref name="pmid19088155">{{cite journal| author=Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER et al.| title=Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 3 | pages= 709-28 | pmid=19088155 | doi=10.1210/jc.2008-1410 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19088155 }} </ref>:=== | ||
Line 54: | Line 54: | ||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | | style="background: #F5F5F5; padding: 5px;text-align: center;" | - | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Insulin autoimmune hypoglycemia | ||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | | style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | ||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>>200<sup>‡</sup> | | style="background: #F5F5F5; padding: 5px;text-align: center;" |>>200<sup>‡</sup> |
Revision as of 13:39, 22 September 2017
Insulinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Insulinoma differential diagnosis On the Web |
American Roentgen Ray Society Images of Insulinoma differential diagnosis |
Risk calculators and risk factors for Insulinoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Insulinoma must be differentiated from other diseases that cause features of hypoglycemia like altered mental status/confusion, profuse sweating and visual disturbances (blurring/diplopia). These are classified on the basis of laboratory findings into exogenous insulin, oral hypoglycemic agents (e.g. sulphonylureas), nesidioblastosis, insulin autoimmune hypoglycemia.
Differentiating insulinoma from other Diseases
- Insulinoma must be differentiated from other diseases that cause features of hypoglycemia. These are classified on the basis of laboratory findings.
Differentials for Hypoglycemia on the basis of Laboratory findings[1]:
Diagnoses | Laboratory Findings differentiating among causes of Hypoglycemia | |||||||
---|---|---|---|---|---|---|---|---|
S.Glucose (mg/dL) |
C Peptide (pmol/L) | S.Insulin (μU/mL) | S.Proinsulin (pmol/L) |
S. Beta hydroxybutyrate | Glucose increase after glucagon(mg/dL) | Oral Hypoglycemic agent | Antibodies to Insulin | |
Normal/Fasting | <55 | <200 | <3 | <5 | >2.7 | <25 | - | - |
Exogenous Insulin | <55 | <200 | >>3 | <5 | ≤2.7 | >25 | - | - |
Insulinoma/Nesidioblastosis/PGPH† | <55 | ≥200 | ≥3 | ≥5 | ≤2.7 | >25 | - | - |
Insulin autoimmune hypoglycemia | <55 | >>200‡ | >>3 | >>5‡ | ≤2.7 | >25 | - | + |
Oral hypoglycemic agent | <55 | ≥200 | ≥3 | ≥5 | ≤2.7 | >25 | + | - |
IGF¤ | <55 | <200 | <3 | <5 | ≤2.7 | >25 | - | - |
† PGPH= Post Gastric Bypass Hypoglycemia,
‡ Free C-peptide and proinsulin concentrations are low
¤ IGF= Insulin Growth Factor, Increased pro-IGF-2, free IGF-2, IGF-2/IGF-1 ratio
References
- ↑ Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.